Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Free Report) was down 0.3% during trading on Friday. The stock traded as low as $0.43 and last traded at $0.4349. 32,733 shares traded hands during mid-day trading, an increase of 26% from the average session volume of 25,953 shares. The stock had previously closed at $0.4360.
Oragenics Price Performance
The business has a 50 day moving average of $0.50 and a 200 day moving average of $0.56. The firm has a market capitalization of $1.96 million, a price-to-earnings ratio of -0.02 and a beta of 1.26.
Oragenics (NYSEAMERICAN:OGEN – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.57) earnings per share (EPS) for the quarter.
Oragenics Company Profile
Oragenics, Inc is a U.S.-based clinical-stage biotechnology company focused on developing intranasal medicines for neurological disorders. Its lead product candidate, ONP-002, is being developed as a potential treatment for concussion and mild traumatic brain injury. The company’s intranasal delivery approach is intended to help deliver therapies directly to the brain while avoiding some limitations associated with conventional administration methods.
Oragenics has also pursued ONP-001, an intranasal product candidate for glioblastoma, an aggressive form of brain cancer.
Further Reading
- Five stocks we like better than Oragenics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
